Derek Archila
Stock Analyst at Wells Fargo
(3.84)
# 730
Out of 4,413 analysts
118
Total ratings
41.94%
Success rate
10.82%
Average return
Main Sectors:
38 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $53 → $52 | $38.82 | +33.95% | 4 | Apr 18, 2024 | |
| ANAB AnaptysBio | Initiates: Overweight | $56 | $21.30 | +162.91% | 1 | Apr 11, 2024 | |
| ANNX Annexon | Maintains: Overweight | $12 | $4.70 | +155.32% | 2 | Apr 1, 2024 | |
| CABA Cabaletta Bio | Maintains: Overweight | $34 → $35 | $10.48 | +233.97% | 5 | Mar 22, 2024 | |
| SLRN Acelyrin | Maintains: Equal-Weight | $11 → $13 | $4.24 | +206.60% | 2 | Mar 21, 2024 | |
| ASND Ascendis Pharma | Maintains: Overweight | $196 → $260 | $140.15 | +85.52% | 9 | Mar 15, 2024 | |
| MOR MorphoSys AG | Downgrades: Equal-Weight | $17 → $18 | $17.36 | +5.13% | 4 | Mar 14, 2024 | |
| ZYME Zymeworks | Maintains: Overweight | $12 → $14 | $8.33 | +68.07% | 2 | Mar 12, 2024 | |
| VTYX Ventyx Biosciences | Upgrades: Overweight | $7 → $16 | $3.84 | +317.21% | 3 | Mar 12, 2024 | |
| ARGX argenx SE | Maintains: Overweight | $472 → $478 | $375.29 | +27.37% | 6 | Feb 20, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $23 → $20 | $12.47 | +60.38% | 4 | Feb 16, 2024 | |
| KYMR Kymera Therapeutics | Downgrades: Equal-Weight | $26 | $34.66 | -24.99% | 5 | Dec 19, 2023 | |
| BPMC Blueprint Medicines | Maintains: Overweight | $86 → $115 | $93.10 | +23.52% | 7 | Dec 19, 2023 | |
| ARVN Arvinas | Upgrades: Overweight | $63 | $31.90 | +97.49% | 3 | Dec 19, 2023 | |
| APLS Apellis Pharmaceuticals | Downgrades: Equal-Weight | $67 → $54 | $47.84 | +12.88% | 7 | Dec 14, 2023 | |
| KZR Kezar Life Sciences | Maintains: Equal-Weight | $4 → $2 | $0.84 | +138.72% | 8 | Nov 14, 2023 | |
| CLDX Celldex Therapeutics | Upgrades: Equal-Weight | $27 | $37.00 | -27.03% | 2 | Nov 10, 2023 | |
| IMVT Immunovant | Maintains: Overweight | $33 → $48 | $27.49 | +74.61% | 8 | Sep 27, 2023 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Overweight | $51 → $50 | $11.42 | +337.83% | 2 | Aug 10, 2023 | |
| MORF Morphic Holding | Maintains: Overweight | $67 → $80 | $27.97 | +186.02% | 5 | Apr 25, 2023 | |
| EXEL Exelixis | Initiates: Overweight | $23 | $23.73 | -3.08% | 1 | Mar 9, 2023 | |
| INCY Incyte | Maintains: Equal-Weight | $72 → $75 | $52.56 | +42.69% | 3 | Jan 3, 2023 | |
| CCCC C4 Therapeutics | Maintains: Equal-Weight | $11 → $9 | $6.32 | +42.41% | 3 | Jan 3, 2023 | |
| GLUE Monte Rosa Therapeutics | Upgrades: Overweight | $19 | $5.61 | +238.68% | 2 | Jan 3, 2023 | |
| ESPR Esperion Therapeutics | Downgrades: Hold | n/a | $1.99 | - | 1 | May 5, 2021 | |
| LUMO Lumos Pharma | Upgrades: Buy | n/a | $2.83 | - | 1 | Mar 11, 2021 | |
| IVA Inventiva | Initiates: Buy | n/a | $3.24 | - | 1 | Aug 4, 2020 | |
| GNFT Genfit | Upgrades: Buy | n/a | $3.52 | - | 1 | Jul 23, 2020 | |
| GLPG Galapagos NV | Downgrades: Hold | n/a | $28.65 | - | 1 | Jul 10, 2020 | |
| OKE ONEOK | Reiterates: Buy | n/a | $81.42 | - | 1 | Apr 15, 2020 | |
| AMRN Amarin Corporation | Maintains: Hold | n/a | $0.88 | - | 2 | Mar 31, 2020 | |
| DBVT DBV Technologies | Downgrades: Hold | n/a | $0.69 | - | 2 | Mar 17, 2020 | |
| VNDA Vanda Pharmaceuticals | Downgrades: Perform | n/a | $4.82 | - | 4 | Dec 11, 2018 | |
| HRTX Heron Therapeutics | Maintains: Outperform | n/a | $2.50 | - | 2 | Jun 22, 2018 | |
| URGN UroGen Pharma | Maintains: Outperform | n/a | $14.04 | - | 1 | Nov 15, 2017 | |
| PRGO Perrigo Company | Initiates: Outperform | n/a | $32.81 | - | 1 | Sep 7, 2017 | |
| PCRX Pacira BioSciences | Initiates: Market Perform | n/a | $26.05 | - | 1 | Sep 7, 2017 | |
| TEVA Teva Pharmaceutical | Downgrades: Perform | n/a | $14.10 | - | 1 | Aug 3, 2017 |
Rhythm Pharmaceuticals
Apr 18, 2024
Maintains: Overweight
Price Target: $53 → $52
Current: $38.82
Upside: +33.95%
AnaptysBio
Apr 11, 2024
Initiates: Overweight
Price Target: $56
Current: $21.30
Upside: +162.91%
Annexon
Apr 1, 2024
Maintains: Overweight
Price Target: $12
Current: $4.70
Upside: +155.32%
Cabaletta Bio
Mar 22, 2024
Maintains: Overweight
Price Target: $34 → $35
Current: $10.48
Upside: +233.97%
Acelyrin
Mar 21, 2024
Maintains: Equal-Weight
Price Target: $11 → $13
Current: $4.24
Upside: +206.60%
Ascendis Pharma
Mar 15, 2024
Maintains: Overweight
Price Target: $196 → $260
Current: $140.15
Upside: +85.52%
MorphoSys AG
Mar 14, 2024
Downgrades: Equal-Weight
Price Target: $17 → $18
Current: $17.36
Upside: +5.13%
Zymeworks
Mar 12, 2024
Maintains: Overweight
Price Target: $12 → $14
Current: $8.33
Upside: +68.07%
Ventyx Biosciences
Mar 12, 2024
Upgrades: Overweight
Price Target: $7 → $16
Current: $3.84
Upside: +317.21%
argenx SE
Feb 20, 2024
Maintains: Overweight
Price Target: $472 → $478
Current: $375.29
Upside: +27.37%
Nurix Therapeutics
Feb 16, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $12.47
Upside: +60.38%
Kymera Therapeutics
Dec 19, 2023
Downgrades: Equal-Weight
Price Target: $26
Current: $34.66
Upside: -24.99%
Blueprint Medicines
Dec 19, 2023
Maintains: Overweight
Price Target: $86 → $115
Current: $93.10
Upside: +23.52%
Arvinas
Dec 19, 2023
Upgrades: Overweight
Price Target: $63
Current: $31.90
Upside: +97.49%
Apellis Pharmaceuticals
Dec 14, 2023
Downgrades: Equal-Weight
Price Target: $67 → $54
Current: $47.84
Upside: +12.88%
Kezar Life Sciences
Nov 14, 2023
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $0.84
Upside: +138.72%
Celldex Therapeutics
Nov 10, 2023
Upgrades: Equal-Weight
Price Target: $27
Current: $37.00
Upside: -27.03%
Immunovant
Sep 27, 2023
Maintains: Overweight
Price Target: $33 → $48
Current: $27.49
Upside: +74.61%
Zentalis Pharmaceuticals
Aug 10, 2023
Maintains: Overweight
Price Target: $51 → $50
Current: $11.42
Upside: +337.83%
Morphic Holding
Apr 25, 2023
Maintains: Overweight
Price Target: $67 → $80
Current: $27.97
Upside: +186.02%
Exelixis
Mar 9, 2023
Initiates: Overweight
Price Target: $23
Current: $23.73
Upside: -3.08%
Incyte
Jan 3, 2023
Maintains: Equal-Weight
Price Target: $72 → $75
Current: $52.56
Upside: +42.69%
C4 Therapeutics
Jan 3, 2023
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $6.32
Upside: +42.41%
Monte Rosa Therapeutics
Jan 3, 2023
Upgrades: Overweight
Price Target: $19
Current: $5.61
Upside: +238.68%
Esperion Therapeutics
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $1.99
Upside: -
Lumos Pharma
Mar 11, 2021
Upgrades: Buy
Price Target: n/a
Current: $2.83
Upside: -
Inventiva
Aug 4, 2020
Initiates: Buy
Price Target: n/a
Current: $3.24
Upside: -
Genfit
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.52
Upside: -
Galapagos NV
Jul 10, 2020
Downgrades: Hold
Price Target: n/a
Current: $28.65
Upside: -
ONEOK
Apr 15, 2020
Reiterates: Buy
Price Target: n/a
Current: $81.42
Upside: -
Amarin Corporation
Mar 31, 2020
Maintains: Hold
Price Target: n/a
Current: $0.88
Upside: -
DBV Technologies
Mar 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $0.69
Upside: -
Vanda Pharmaceuticals
Dec 11, 2018
Downgrades: Perform
Price Target: n/a
Current: $4.82
Upside: -
Heron Therapeutics
Jun 22, 2018
Maintains: Outperform
Price Target: n/a
Current: $2.50
Upside: -
UroGen Pharma
Nov 15, 2017
Maintains: Outperform
Price Target: n/a
Current: $14.04
Upside: -
Perrigo Company
Sep 7, 2017
Initiates: Outperform
Price Target: n/a
Current: $32.81
Upside: -
Pacira BioSciences
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $26.05
Upside: -
Teva Pharmaceutical
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $14.10
Upside: -